Meeting
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Edmond Michael Kwan
School of Clinical Sciences, Monash University, Melbourne, VIC, Australia
Edmond Michael Kwan , Sarah Q To , Heidi C Fettke , Maria M Docanto , Patricia Bukczynska , Andrew Michael Mant , David William Pook , Nicole Ng , Lisa-Jane K Graham , Eva Segelov , Kate Mahon , Ian D. Davis , Phillip Parente , Carmel Jo Pezaro , Lisa Horvath , Arun Azad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 188)
DOI
10.1200/JCO.2019.37.7_suppl.188
Abstract #
188
Poster Bd #
H9
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis
Poster
2014 ASCO Annual Meeting
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Peter Petrylak
Poster
2023 ASCO Annual Meeting
PSMA expression and response to 177Lu-PSMA-617 (LuPSMA) in men with vs. without DNA damage repair (DDR) mutations.
First Author: Ruben Raychaudhuri
Poster
2023 ASCO Genitourinary Cancers Symposium
Characteristics of long-term responder (LTR) patients (pts) treated with androgen-receptor signaling inhibitors (ARSI) as a first-line treatment for metastatic castration-resistant prostate cancer (mCRPC): Real-world evidence from four high-volume institutions.
First Author: Orazio Caffo